Individuals with cancer often exhibit dysfunctional immune signaling in response to interferon (IFN) stimulation. Furthermore, recent evidence indicates that pSTAT-1 levels, which are indicative of IFN responsiveness, in circulating immune cells are predictive of clinical outcome in melanoma patients.
More...
More...